ENDV Stock Overview
A biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Endonovo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0004 |
| 52 Week High | US$0.013 |
| 52 Week Low | US$0.0004 |
| Beta | -0.62 |
| 1 Month Change | -50.00% |
| 3 Month Change | -60.00% |
| 1 Year Change | -95.27% |
| 3 Year Change | -97.56% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENDV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -27.3% | 2.6% | 2.8% |
| 1Y | -95.3% | -3.3% | 24.6% |
Return vs Industry: ENDV underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: ENDV underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| ENDV volatility | |
|---|---|
| ENDV Average Weekly Movement | 29.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENDV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENDV's weekly volatility has decreased from 37% to 30% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Alan Collier | www.endonovo.com |
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis.
Endonovo Therapeutics, Inc. Fundamentals Summary
| ENDV fundamental statistics | |
|---|---|
| Market cap | US$158.73k |
| Earnings (TTM) | -US$4.40m |
| Revenue (TTM) | US$255.72k |
0.6x
P/S Ratio0.0x
P/E RatioIs ENDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDV income statement (TTM) | |
|---|---|
| Revenue | US$255.72k |
| Cost of Revenue | US$9.69k |
| Gross Profit | US$246.03k |
| Other Expenses | US$4.65m |
| Earnings | -US$4.40m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 96.21% |
| Net Profit Margin | -1,722.23% |
| Debt/Equity Ratio | -30.7% |
How did ENDV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 12:04 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Endonovo Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | SeeThruEquity, LLC |